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Background: Bladder cancer is one of the most common cancers in Europe, the United States, 
and Northern African countries. Muscle-invasive bladder cancer is an aggressive epithelial 
tumor, with a high rate of early systemic dissemination. Superficial, noninvasive bladder cancer 
can most often be cured; a good proportion of invasive cases can also be cured by a combined 
modality approach of surgery, chemotherapy, and radiation. Recurrences are common and 
mostly manifest as metastatic disease. Those with distant metastatic disease can sometime 
achieve partial or complete remission with combination chemotherapy.
Recent developments: Better understanding of the biology of the disease has led to the 
incorporation of molecular and genetic features along with factors such as tumor grade, lympho-
vascular invasion, and aberrant histology, thereby allowing identification of ‘favorable’ and 
‘unfavorable’ cancers which helps a more accurate informed and objective selection of patients 
who would benefit from neoadjuvant and adjuvant chemotherapy. Gene expression profiling 
has been used to find molecular signature patterns that can potentially be predictive of drug 
sensitivity and metastasis. Understanding the molecular pathways of invasive bladder cancer 
has led to clinical investigation of several targeted therapeutics such as anti-angiogenics, mTOR 
inhibitors, and anti-EGFR agents.
Conclusion: With improvements in the understanding of the biology of bladder cancer, 
clinical trials studying novel and targeted agents alone or in combination with chemotherapy 
have increased the armamentarium for the treatment of bladder cancer. Although the novel 
biomarkers and gene expression profiles have been shown to provide important predictive and 
prognostic information and are anticipated to be incorporated in clinical decision-making, their 
exact utility and relevance calls for a larger prospective validation.
Keywords: bladder cancer, chemotherapy, biologic therapy, neoadjuvant, PI3kinase/mTOR 
pathway
Introduction
Bladder cancer occurs mostly in men. An estimated 386,300 new cases and 150,200 
deaths from bladder cancer occurred in 2008 worldwide.1 Its incidence varies widely 
internationally, with the highest incidence rates found in Europe, the United States, 
and northern African countries, while the lowest rates are found in the countries of 
  Melanesia and middle Africa. Smoking and occupational exposures (dye, arsenic, 
aromatic amines, rubber or leather industries) are the major risk factors in Western 
countries, whereas chronic infection with Schistosoma hematobium accounts for about 
50% of the total burden in developing countries.1,2 It is the fourth most common malig-
nancy diagnosed in the US with estimates of 70,530 (52,760 men and 17,770 women) OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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new cases and 14,680 (10,410 men and 4270 women) deaths 
for the year 2010.1 The approximate 5:1 ratio of incidence 
to mortality reflects the frequency of superficial tumor com-
pared with invasive and metastatic disease.
Histologically, there are three types of bladder cancer 
arising from the epithelium lining of the bladder. Transitional 
cell carcinoma, which begins in the cells lining the inner most 
tissue layer of the bladder, accounts for more than 90% of 
bladder tumors. Squamous cell carcinomas, which arise from 
the squamous cells of the bladder epithelium, constitute about 
6% to 8% of bladder tumors and are usually associated with 
long-term infection or irritation of the bladder epithelium. 
Adenocarcinomas, which account for about 2% of bladder 
neoplasms, usually arise from the glandular (secretory) cells 
and often have urachal origin.3 The three general categories of 
bladder cancer – superficial, invasive and metastatic –   differ 
in their biology, phenotype, prognosis, and management. 
Superficial bladder cancers, which include papillary carci-
noma (Ta), carcinoma in situ ‘flat tumors’ (CIS) and tumors 
that invade subepithelial connective tissue (T1) account for 
about 70% of newly diagnosed urothelial bladder cancer. The 
initial treatment of ‘nonmuscle-invasive’ superficial bladder 
cancer is a complete cystoscopic transurethral resection of 
all visible tumor, usually carried out at the time of diagnosis, 
followed by adjuvant intravesical therapy with BCG (a live 
attenuated form of Mycobacterium bovis) or less commonly 
with mitomycin, valrubicin, gemcitabine, or thiotepa.4 
Despite aggressive treatment approximately 25% of these 
patients with nonmuscle-invasive superficial bladder cancer 
develop an invasive and metastatic form of disease.5
Muscle-invasive bladder cancer is an aggressive epithe-
lial tumor with a high rate of early systemic dissemination 
and poor long-term survival; almost 50% of these patients 
develop metastases and ultimately succumb to their disease.6,7 
The most common site of metastasis of urothelial carcinoma 
is to the regional lymph nodes (78%); other common meta-
static sites include liver (38%), lung (36%), bone (27%), 
adrenal gland (21%), and intestine (13%).8 In the same 
series, Babaian and colleagues had reported metastases to 
the heart, brain, kidney, spleen, pancreas, meninges, uterus, 
ovary, prostate, and testes in 1% to 8% of their patients.8 
Although only one-third of newly diagnosed bladder cancers 
are advanced at presentation, another 15% to 30% of high-
grade superficial tumors progress to muscle-invasive tumors 
usually within 5 years.6,7,9
In this article, we discuss the current multimodality 
strategies including systemic chemo/biologic therapies 
in combination with surgery and/or radiation applicable 
for invasive and metastatic bladder cancers, and various 
prognostic and predictive factors to determine therapeutic 
outcomes and potential for treatment-related toxicities. We 
performed a systematic review of peer-reviewed publications 
identified through searches of MEDLINE/PubMed from 
March 2005 to March 2011. We also included results of 
the relevant clinical trials presented at the annual oncology 
meetings (eg, Annual Meeting of American Society of Clini-
cal Oncology [ASCO]). The ongoing Phase II and Phase III 
trials for first- and second-line chemotherapy for invasive 
and metastatic bladder cancer were searched from the US 
National Institute of Health’s web resource, clinicaltrials.gov, 
which is a registry of clinical trials conducted in the US and 
worldwide. Keywords were used alone and with the modi-
fiers of treatment, novel therapies, invasive and metastatic 
bladder cancer, and biomarkers. Bibliographies from these 
references were reviewed.   Criteria used for study selection 
included study design, English language, relevance to clini-
cians, and validity based on the venue of publication.
Staging considerations  
in bladder cancer
Clinical assessment of primary tumor includes bimanual 
examination under anesthesia before and after endoscopic 
biopsy or resection and histological verification for the pres-
ence of tumor. Finding of bladder wall thickening, or a fixed 
mass suggest the presence of an invasive disease. Appropriate 
imaging studies such as a computed tomography or magnetic 
resonance imaging should be incorporated into clinical stag-
ing to assess the extravesical extension of the tumor and 
lymph node evaluation, but one should take caution for there 
is a potential for an overestimation or even underestimation 
of the stage of the tumor. The ability of these studies to 
determine degree of muscle invasiveness preoperatively is 
modest and pathologic staging is usually needed to confirm 
the extent of the disease. Detailed staging information is not 
discussed here;10 in the context of this article, according to the 
2010 American Joint Committee on Cancer (AJCC) cancer 
staging system, muscle infiltrating disease is considered T2. 
It is further subdivided into T2a (inner half) or T2b (outer 
half), but with disease still confined within the bladder. T3 
lesions extend beyond muscle into the perivesical fat. T4 
lesion are those extending into adjacent organs – tumors 
invading the prostatic stroma, vagina, uterus, or bowel are 
classified as T4a, while those fixed to the abdominal wall, 
pelvic wall, or other organs are classified as T4b. A single 
lymph node metastasis in the true pelvis is considered N1 
disease, while multiple nodal involvement in the true pelvis OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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is N2 disease, and involvement of the common iliac nodes is 
staged as N3. Presence of distant metastatic disease (eg, lung, 
liver, bones) is classified as M stage. The number of lymph 
nodes examined from the operative specimen and the number 
of positive lymph nodes have been reported to be associated 
with survival.11–13 In addition, the size of the largest tumor 
deposit and presence of extra-nodal extension may inde-
pendently affect survival.14 Adequate lymph node sampling 
should include an average of .12 lymph nodes.10
Prognostic and predictive markers 
for bladder cancer
The most important prognostic determinants in bladder 
cancer are the tumor grade and stage (whether the tumor is 
organ-confined or nonorgan-confined). However, conven-
tional histopathologic evaluation criteria are limited in their 
ability to accurately predict tumor behavior. A number of 
clinical and molecular characteristics are correlated with the 
response to chemotherapy and survival. Poor performance 
status and presence of visceral (eg, pulmonary, liver, skeletal) 
metastatic disease are correlated with decreased survival. 
This was demonstrated in the intergroup trial that compared 
cisplatin alone with methotrexate, vinblastine, doxorubicin, 
and cisplatin (M-VAC) in patients with metastatic disease.15 
The median survival of the group with favorable features 
was 18.2 vs 4.4 months for the group with unfavorable 
features. In the long-term follow-up results of this trial, no 
patients with liver or bone metastases and only one patient 
with a Karnofsky performance status ,80 survived 6 years.16 
Subsequent reports have also confirmed the relationship 
between shortened survival and poor performance status or 
the presence of visceral metastases.17,18
Prediction tools, also known as ‘nomograms’, developed 
based on retrospective multivariate analysis to predict prob-
ability of extravesical extension or nodal metastasis at radical 
cystectomy, estimate the risk of recurrence and survival after 
cystectomy in bladder cancer and are currently available for 
clinical use.19–21 One such nomogram developed by Inter-
national Bladder Cancer Nomogram Consortium (http://
www.mskcc.org/applications/nomograms/bladder) is based 
on a retrospective multivariate analysis of more than 9000 
patients from twelve centers of excellence worldwide.20 This 
nomogram estimates probability of remaining disease free at 
5 years after cystectomy based on patient age, sex, time from 
diagnosis to surgery, pathologic tumor stage and grade, tumor 
histologic subtype, and regional lymph node status. The pre-
dictive accuracy of the constructed international nomogram 
(concordance index, 0.75) is significantly better than standard 
AJCC TNM staging (concordance index, 0.68; P , 0.001) 
or standard pathologic subgroupings (concordance index, 
0.62; P , 0.001). These nomograms do not make treatment 
recommendations, but simply provide a means to predict an 
advanced stage and assess individual patient risk for disease 
recurrence, and survival – all key factors in deciding the 
need for additional treatments in the form of neoadjuvant or 
adjuvant therapies. These predictive tools can be accessed 
online at http://www.nomograms.org.
Several studies on molecular alterations as markers for 
prognostication have been reported with the goal of using 
these molecular markers of an individual tumor to help select 
appropriate therapy. P53 is the most widely investigated 
molecular marker in bladder cancer. Overexpression of P53 
detected by immunohistochemistry (IHC) which infers muta-
tion of TP53 gene has been demonstrated to be a predictor of 
poor survival in patients with advanced bladder cancer.22–24 
In a report of 90 patients undergoing neoadjuvant M-VAC 
chemotherapy, those who harbored mutant P53 were three 
times more likely to die from their disease than those with 
wild-type P53.25 Ki-67 index is also significantly greater in 
high-grade tumors and in those overexpressing P53; high 
Ki-67 index (.32% staining in IHC) is predictive of poor 
prognosis.23 Positive staining for pro-apoptotic markers – 
Bax and CD40 L – is shown to predict improved survival 
while positive staining for anti-apoptotic marker – Bcl-2 – is 
correlated with poor survival.26,27 However, there have been 
inconsistencies in these findings which may be due to arbi-
trary cut-off levels for positive or negative expression based 
on the level of IHC staining.
Molecular profiling and proteomics can provide better 
indicators of tumor behavior, and may become available for 
routine clinical practice.28,29 A recent report from a German 
group30 on the gene expression analysis of chemotherapy 
response modifiers multidrug resistance gene 1 (MDR1) and 
excision repair cross-complementing 1 (ERCC1) performed 
on tumor samples from patients undergoing adjuvant che-
motherapy for locally advanced bladder cancer showed that 
expression of MDR1 and ERCC1 were independently associ-
ated with overall progression-free survival (PFS) with rela-
tive risk of 2.9 and 2.24, respectively. In another study of 57 
patients with advanced bladder cancer treated with cisplatin-
based regimen, the median survival was significantly longer 
in patients with low ERCC1 levels.31 The MDR1 gene product 
P-glycoprotein (Pgp) is an energy-dependent efflux pump, 
which, among others, reduces intracellular concentrations of 
certain chemotherapeutic drugs including anthracyclines and 
vinka alkaloids, both of which are components of M-VAC OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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regimen. Although cisplatin is not considered a de novo sub-
strate of Pgp, studies have suggested an altered expression 
of MDR1 after cisplatin administration, possibly resulting in 
decreased cytotoxic efficacy.32 ERCC1 gene is involved in 
DNA repair and may mediate resistance to alkylating agents. 
Recently, a 20-gene gene expression model was reported 
to be effective in predicting the pathological nodal status, 
thereby allowing selecting high-risk patients for neoadjuvant 
chemotherapy on the basis of risk of node-positive disease, 
while sparing others from toxic side-effects, and the delay 
to cystectomy.33
Currently, research on molecular prognostication of 
invasive bladder cancer is still in its infancy and the data 
generated from this work are primitive, but research certainly 
holds promise for future personalization of therapy by bet-
ter understanding the biology of the disease, matching the 
appropriate group of patients with the right drug combina-
tion, and estimating the efficacy of those chemotherapeutic 
and biologic agents.
Management of muscle-invasive 
bladder cancer
The standard treatment approach for patients with localized 
muscle-invasive bladder cancer is radical cystectomy with 
urinary diversion. Reconstructive techniques such as ileal 
conduit, catheterizable pouch, and neo-bladder eliminate 
the need for external drainage devices in some male patients 
and provide improved quality of life for those who undergo 
radical cystectomy. Radical cystectomy requires removal 
of the bladder, adjacent organs, and regional lymph nodes. 
In men, it generally includes removal of the prostate and 
seminal vesicles, along with the urinary bladder, and in 
women, removal of the uterus, cervix, ovaries, and anterior 
vagina is usually performed en bloc with the bladder. Despite 
undergoing such ‘radical’ surgery, several patients are at 
risk of developing distant metastases and also loco-regional 
recurrence with second primary urothelial tumors in the 
renal pelvis, ureters, or urethra. Multimodality approaches 
in the form of neoadjuvant or adjuvant chemotherapy have 
been evaluated in randomized trials and are currently applied 
clinically to decrease relapses and increase cure rates. Result 
of such contemporary clinical trials in both neoadjuvant and 
adjuvant settings will be discussed in this section.
Neoadjuvant therapy
In patients with muscle-invasive bladder cancer, the most 
important treatment-related issues include the identifica-
tion of those who can be cured with radical cystectomy 
alone, and those who, due to high risk of recurrence or 
metastasis, require a multimodality approach to achieve 
cure. For long, radical cystectomy has been considered the 
standard approach for patients with muscle-invasive blad-
der cancer. Despite a curative surgery, about half of these 
patients develop metastatic disease within 2 years, with a 
high mortality among those developing metastatic disease.6,34 
Administering cisplatin-based systemic chemotherapy either 
before (neoadjuvantly) or after (adjuvantly) cystectomy 
has a potential to eradicate micrometastatic disease, and 
thereby improve survival in this group of patients. Hence, 
neoadjuvant chemotherapy followed by radical cystectomy 
is now considered by many as the new standard of care for 
this disease. The advantages of neoadjuvant therapy include 
delivery of chemotherapy through intact vasculature, which 
is often affected by surgery, and downsizing the tumor 
prior to cystectomy, thereby increasing complete resection 
with a likelihood of long-term remission and/or survival in 
such patients. Patients often tolerate greater dose intensity 
and more cycles of chemotherapy preoperatively than post-
operatively.35 The disadvantage of such therapy is the delay 
of definitive local therapy in patients who do not respond to 
neoadjuvant chemotherapy and it could potentially be associ-
ated with disease   progression. Results of several randomized 
clinical trials36–40 and a meta-analysis of all neoadjuvant 
studies in bladder cancer41 have favored this approach of 
platinum-based, multiagent, neoadjuvant chemotherapy fol-
lowed by cystectomy over cystectomy alone (Table 1).
The largest neoadjuvant chemotherapy trial (BA06 
30894) was conducted jointly by the Medical Research 
Council (MRC), the European Organization for Research 
and Treatment of Cancer (EORTC), and several interna-
tional collaborators.36 In total, 976 patients with high-grade 
T2-T4a urothelial bladder cancer accrued over 5.5 years from 
106 institutions were randomly assigned to three cycles of 
neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) 
chemotherapy (n = 491) or no chemotherapy (n = 485), fol-
lowed by institution’s choice of definitive therapy with either 
radical cystectomy and/or radiation therapy. Of patients in the 
chemotherapy and no-chemotherapy groups 42% and 43%, 
respectively, received radiation therapy alone as definitive 
therapy. Pathologic complete response (pCR) with neoad-
juvant chemotherapy was 33%. Overall survival (OS) at 3 
years in the two groups was 55.5% vs 50%, respectively, 
with an absolute survival benefit of 5.5% favoring the 
chemotherapy group. However, the prespecified statistical 
aim to detect an absolute survival improvement of 10% 
(from 50% to 60%) was not met. The most recent update,42 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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after 8 years of follow-up, showed a statistically significant 
16% reduction in the risk for death in patients who received 
neoadjuvant CMV prior to radiotherapy and/or cystectomy; 
this corresponds to an increase in 3-year survival from 50% 
to 56%, an increase in 10-year survival from 30% to 36%, 
and an increase in median survival time of 7 months (from 
37 to 44 months) in CMV-treated patients compared with 
those treated with local therapy only.
In a US Intergroup trial (INT 0080),38 307 of the 317 
enrolled patients with T2-T4a urothelial bladder cancer were 
randomized to three cycles of neoadjuvant M-VAC (n = 154) 
or no chemotherapy (n = 153) followed by cystectomy. The 
study took almost 13 years to complete accrual. pCR with 
neoadjuvant M-VAC chemotherapy was 38%. Median 
follow-up was 8.7 years. Patients who received M-VAC 
showed a trend towards improvement in median OS (77 vs 
46 months, P = 0.06). A subsequent retrospective analysis 
showed that after adjustment for pathologic factors and 
neoadjuvant chemotherapy use, an optimal cystectomy and 
thorough pelvic node dissection, defined as negative resection 
margins and at least 10 lymph nodes in the surgical specimen, 
was associated with longer survival (.80% at 5 years).43 
Another recent secondary analysis of this study showed that 
presence of squamous or glandular differentiation in locally 
advanced urothelial bladder cancer does not confer resistance 
to M-VAC, and in fact, may be an indication for the use of 
neoadjuvant chemotherapy before radical cystectomy.44
Randomized clinical trials (Nordic37,39 and GISTV ,40 
Table 1) did not demonstrate survival difference using neo-
adjuvant chemotherapy.
Majority of the randomized clinical trials have not dem-
onstrated a survival benefit with the addition of neoadjuvant 
chemotherapy. Inadequate sample size, suboptimal chemo-
therapy, premature closure, and/or inadequate follow-up 
have all been attributed to these negative results. Hence, 
meta-analyses have been performed to interpret these data. 
An update of a systematic review and meta-analysis of clini-
cal trials of neoadjuvant chemotherapy in invasive bladder 
cancer was published by Advanced Bladder Cancer meta-
analysis collaboration.41 In patients who received cisplatin-
based combination chemotherapy prior to cystectomy, a 5% 
absolute benefit improving survival from 45% to 50% at 
5 years (P = 0.003) was observed. No information was 
reported about the quality of life and toxicities from various 
chemotherapeutic regimens used. Most patients from the 
EORTC/MRC, INT 0080, and Nordic studies were young, 
with a median age of 63 to 65 years with excellent perfor-
mance status and good renal function; hence, there remains 
a question as to whether these results can be applied to most 
of the elderly patients who form the major proportion of the 
bladder cancer population.
Regimens such as gemcitabine plus cisplatin (GC), which 
in metastatic setting is shown to be less toxic and achieves 
similar response rates and survival,45 has not been tested 
prospectively in the neoadjuvant setting. A recent single-
institution retrospective study by Dash et al46 showed a pCR 
of 26% with GC which is comparable to other cisplatin-based 
regimens. A combination of a taxane, nab-paclitaxel, along 
with gemcitabine and carboplatin in a neoadjuvant setting 
was recently reported.47 In this Phase II trial, 27 eligible 
patients with T2-T4, N0, or any T, N1–3 bladder cancer 
were treated with three cycles of nab-paclitaxel along with 
gemcitabine and carboplatin, followed by cystectomy. 
Of the 27 patients, 25 completed all three cycles. Grade 
3–4   neutropenia was seen in all patients. pCR, the primary 
endpoint, was seen in 30% of the patients with 25% demon-
strating CIS. This combination appears to be an active regi-
men and could be of potential benefit in patients who are not 
Table 1 Results of randomized clinical trials evaluating neoadjuvant chemotherapy for muscle-invasive bladder cancer
Study N Regimen Comparator pCR OS
eORTC/MRC36 976 CMV (3 cycles) followed by  
cystectomy or RT (n = 491)
Cystectomy or RT  
(n = 485)
33% 5.5% in favor of CMV
iNT 0080/SwOG 871038 317 M-VAC (3 cycles) followed  
by cystectomy (n = 154)
Cystectomy  
(n = 153)
38% Trend in benefit with   
M-VAC (P = 0.06)
Nordic39 325 CA (2 cycles) followed by  
cystectomy or RT (n = 151)
Cystectomy or RT  
(n = 160)
NR No difference
Nordic 237 317 CM (3 cycles) followed  
by cystectomy (n = 155)
Cystectomy  
(n = 154)
26.4% No difference
italy (GiSTV)40 171 M-VeC (3 cycles) followed  
by cystectomy (n = 82)
Cystectomy  
(n = 71)
28% No difference
Abbreviations: pCR, pathologic complete response; OS, overall survival; CMV, cisplatin + methotrexate + vinblastine; M-VAC, methotrexate + vinblastine + adriamycin + 
cisplatin; NR, not reported; CA, cisplatin + adriamycin; CM, cisplatin + methotrexate; M-VeC, methotrexate + vinblastine + epirubicin + cisplatin; SwOG, South west 
Oncology Group; RT, radiotherapy.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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candidates for cisplatin. Blick et al48 reported a retrospective 
study of 80 patients who underwent accelerated M-VAC 
therapy administered at 2-week intervals with granulocyte 
colony-stimulating factor (G-CSF) support in an attempt to 
minimize delay to definitive therapy and improve efficacy 
of neoadjuvant chemotherapy. All planned cycles of che-
motherapy were completed by 84% of patients and median 
duration of chemotherapy was 34 days. All 80 patients 
received their planned definitive therapy (cystectomy in 60 
patients; radiotherapy in 20 patients). pCR was seen in 43% 
of patients treated with surgery with an objective radiological 
response in 75% of patients. There were no treatment-related 
deaths, and incidence of grade $3 toxicities was 11%. 
Accelerated M-VAC appears to be a safe and well-tolerated 
regimen that needs to be prospectively evaluated. Although 
these newer regimens are promising, there are no data yet 
from well-powered randomized trials supporting their use. 
For those patients with inter-current illnesses that prohibit 
use of M-VAC, GC may constitute a reasonable alternative. 
Several clinical trials are evaluating biologic agents along 
with chemotherapeutic combinations in a neoadjuvant setting 
as listed in Table 2.
Addition of radiation therapy to chemotherapy in the neo-
adjuvant setting has been investigated in randomized studies 
with equivocal results; hence this approach is not considered 
a standard-of-care. The results of these trials will not be dis-
cussed here but are available for review elsewhere.49–52
The primary goal of muscle-invasive bladder cancer 
treatment is cure, and bladder preservation is a secondary 
consideration. Organ-sparing approaches are considered as 
an alternative, particularly in frail and very elderly patients 
and those with significant medical co-morbidities or those 
who will not accept the side-effects and risks associated with 
surgery. Avoidance of radical cystectomy as a reasonable 
approach in those patients who have a complete response 
to neoadjuvant therapy has been investigated in a few clini-
cal trials. Herr et al53 have reported a nonrandomized study 
with 111 patients with T2–3, N0, M0 urothelial cancer who 
received neoadjuvant M-VAC chemotherapy. Forty-three 
of the 60 patients who achieved complete clinical response 
(cT0) underwent bladder-sparing surgery (transurethral 
resection of bladder tumor [TURBT] alone in 28 patients; 
partial cystectomy in 15 patients) while 17 underwent radical 
cystectomy. At 10 years, 32 of the 43 patients (75%) who 
underwent bladder-sparing surgery were alive. These results 
were similar to the group who underwent radical cystectomy 
(65% survival at 10 years). However the bladder remained at 
risk for new invasive tumors (24 patients, 56% relapse), most 
requiring salvage cystectomy. In a similar study reported by 
Sternberg et al,54 104 patients with T2-T4a urothelial cancer 
who received neoadjuvant therapy with M-VAC, were fol-
lowed by bladder-sparing surgery in 65 patients (TURBT 
alone in 52 patients; partial cystectomy in 13 patients) while 
39 patients had radical cystectomy based on the degree of 
response to chemotherapy. The estimated 5-year survival 
in the group undergoing bladder-sparing surgery was 
67% compared with 46% in group who underwent radical 
  cystectomy. However, a more recent Phase II clinical trial 
reported by deVere et al55 showed that though the complete 
clinical response (cT0) by TURBT following neoadjuvant 
therapy (with gemcitabine, carboplatin, and paclitaxel) was 
46%, there was an unacceptably high rate (60%) of persistent 
Table 2 Active clinical trials evaluating neoadjuvant chemotherapy for muscle invasive bladder cancer100
Study identifier Phase Study drug Start date Primary endpoint
NCT00585689 ii gemcitabine + carboplatin + nab-paclitaxel December 2007 pCR
NCT00706641 Pilot (0) dasatinib June 2008 Feasibility
NCT01245660 Pilot (0) lapatinib November 2010 effect on eGF pathway
NCT00847015 ii gemcitabine + cisplatin + sunitinib February 2009 pCR, safety
NCT00506155 ii M-VAC + bevacizumab July 2007 pCR
NCT01222676 ii gemcitabine + cisplatin + sorafenib October 2010 pCR
NCT01031420 ii dose-dense M-VAC December 2009 pCR
NCT01094496 (N-ABLe) ii gemcitabine + cisplatin ± CDX-1307  
vaccine (for tumors expressing β-hcg)
March 2010 RFS
NCT00268450 ii neoadjuvant gemcitabine + cisplatin +  
bevacizumab, followed by surgery and  
adjuvant bevacizumab and paclitaxel
December 2005 pCR
NCT00749892 ii erlotinib September 2008 pCR
NCT00136175 ii gemcitabine + carboplatin + paclitaxel August 2005 pCR
NCT01093066 ii M-VAC follwed by optimal TURBT April 2010 BPR
Abbreviations: pCR, pathologic complete response; eGF, epithelial growth factor; M-VAC, methotrexate + vinblastine + adriamycin + cisplatin; RFS, recurrence-free 
survival; BPR, bladder preservation rate; TURBT, transurethral resection of bladder tumor.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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cancer at cystectomy in patients presumed to have pT0 status. 
The authors concluded that patients completing neoadjuvant 
chemotherapy should strongly consider definitive local 
therapy regardless of post-chemotherapy cT0 status. Based 
on these studies, one can infer that a considerable number of 
patients whose invasive tumors are significantly downsized 
with combination chemotherapy may be curable by conserva-
tive surgery such as partial cystectomy, rather than a radical 
cystectomy; however, downsizing with neoadjuvant therapy 
does not necessarily ensure complete local control of disease, 
especially with a high risk of metachronous bladder cancer 
in these patients.
Adjuvant therapy
Unlike neoadjuvant treatment, adjuvant chemotherapy can 
be tailored according to the pathologic staging prior to 
administration of systemic therapy, thereby limiting toxic-
ity associated with such treatment and also avoiding any 
delay in potentially curative surgery in those patients whose 
tumor is not responsive to cytoreductive chemotherapy. 
The availability of adequate tissue for analysis of molecular 
prognostic and predictive markers may be another advantage. 
The disadvantage of adjuvant therapy is that there could be 
delay in initiating systemic therapy for occult metastatic 
disease while treating the primary focus; in some surgically 
debilitated and elderly patients, it can be very challenging 
and sometimes may not be possible to administer adequate 
systemic chemotherapy following cystectomy.
Similar to neoadjuvant setting, there are several random-
ized clinical trials reported in the adjuvant setting which 
have conflicting results and with caveats such as inadequate 
sample size, flawed clinical trial design, and poor accrual 
leading to early termination. The older trials have been 
reviewed elsewhere.56 A systematic review and meta-analysis 
of individual patient data from those trials was published in 
2005.57 The results, based on 491 patients from six trials, rep-
resenting 90% of all patients randomized in cisplatin-based 
combination chemotherapy trials and 66% of patients from 
all eligible trials, suggested a 25% relative reduction in the 
risk of death for chemotherapy compared with that on control, 
with an overall hazard ratio for survival of 0.75 (P = 0.019). 
It concluded that there was insufficient evidence on which to 
reliably base treatment decisions. The contemporary coopera-
tive trials will be reviewed in this section.
In an Italian multicenter randomized Phase III trial,58 
patients with pT2G3, pT3-4, N0-2 transitional cell bladder 
carcinoma, after radical cystectomy, were assigned to four 
cycles of GC or observation followed by same chemotherapy 
at progression. Only 194 patients were enrolled (32% of the 
target) and the trial was stopped due to poor accrual. At a 
median follow-up of 32.5 months, relapses were similar in 
both groups (43% vs 45%) with no difference in disease-free 
survival (DFS). The 3-year OS was 67% for the chemother-
apy arm and 48% for the observation arm and the 3-year DFS 
was 47% and 35%, respectively, suggesting no improvement 
in OS or DFS with adjuvant GC in these patients.
In a clinical trial conducted by the Southwest Oncology 
Group,59 499 patients post-radical cystectomy for urothelial 
cancer with pT1-T2, N0 disease were assessed for P53 
expression. Those positive for P53 expression with $10% 
nuclear reactivity by IHC were randomly assigned to observa-
tion vs three cycles of adjuvant M-VAC. Primary endpoint 
was recurrence-free survival. The trial was terminated after 
a planned interim analysis due to futility. Among the 114 
patients with P53-positive tumors who were randomized to 
observation or adjuvant chemotherapy, there were no differ-
ences in time to recurrence or OS. In the entire cohort, the 
study did not confirm the prognostic value of P53 expression 
by IHC for either recurrence or OS.
In the randomized Phase III Spanish Oncology 
Genitourinary Group trial 99/01,60 patients with high-risk 
  muscle-invasive bladder cancer (pT3-4 and/or node-positive 
disease) were assigned to four courses of chemotherapy 
with paclitaxel, gemcitabine, and cisplatin combination 
or observation. The primary objective was OS. The study 
was opened in July 2000 and prematurely closed in July 
2007 due to poor recruitment, with 142 patients random-
ized (74 to observation and 68 to chemotherapy). At a 
median follow-up of 51 months, there was a statistically 
significant increase in OS with chemotherapy compared with 
observation. Five-year OS was 60% vs 31% respectively. 
Secondary endpoints such as DFS, time-to-progression 
(TTP) and disease-specific survival were also superior in 
the chemotherapy arm. Importantly, this abstract reports a 
post-hoc review of a study that was closed early to accrual, 
and further follow-up and peer review will be required before 
it can be viewed as definitive.
A large Phase III trial by EORTC (protocol #30994) 
evaluating observation vs adjuvant chemotherapy with one of 
the three chemotherapy regimens (GC, M-VAC, or high-dose 
M-VAC) in high risk bladder cancer (pT3-4 and/or node-
positive disease) was also prematurely closed in August 2008 
due to poor accrual after enrolment of 278 patients; another 
large 800-patient trial by the Cancer and Leukemia Group B 
evaluating role of high-dose intensity chemotherapy vs stan-
dard chemotherapy in the adjuvant setting also   suffered from OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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poor accrual that led to its early closure. Results of these 
trials are currently not available.
Based on the older clinical trials, meta-analysis, and the 
contemporary clinical trials in the adjuvant setting, there 
appears to be no clear evidence for the role of adjuvant 
chemotherapy in locally advanced bladder cancer. Patients 
are encouraged to participate in such clinical trials whenever 
possible. In patients with pT2, N0 urothelial bladder cancer, 
following cystectomy with observation seems to be a rational 
approach while for those patients with pT3-4 and/or node-
positive disease, following cystectomy with four cycles of 
chemotherapy with M-VAC or GC appears reasonable since 
these regimens have shown significant activity in metastatic 
setting.
Management of metastatic  
bladder cancer
First-line therapy
The standard approach for patients with inoperable locally 
advanced or metastatic disease is systemic chemotherapy. 
Urothelial bladder cancer is highly responsive to cisplatin-
based chemotherapy; however, the median survival even with 
aggressive chemotherapy is only about 15 months. Several 
chemotherapeutic drugs such as cisplatin, methotrexate, 
adriamycin, ifosfamide, docetaxel, and gemcitabine have 
shown to have single-agent activity in either first-line or 
subsequent therapy of metastatic bladder cancer, but with 
low overall response rates (ORR) and short duration of 
responses.61–66 This led to development of cisplatin-based 
combination regimens.
In a randomized trial of 108 patients, comparing cis-
platin with cisplatin plus methotrexate,67 the combination 
demonstrated a response rate of 45% vs 31% compared with 
single-agent cisplatin, which was not significantly different. 
There was an improved TTP but no difference in survival. 
In a 58-patient cohort with metastatic transitional cell carci-
noma, combination of cisplatin, methotrexate, and vinblastine 
showed an ORR of 56% with a complete response rate (CR) 
of 28%. Patients who had achieved CR showed a prolonged 
DFS of 11 months.
M-VAC regimen in a nonrandomized clinical trial68 of 
133 patients with advanced urothelial tract cancer showed 
tumor regression in about 72% of cases and 36% of those 
achieved CR; 3-year survival was 55% among patients 
who had a CR. Further, in a prospective randomized inter-
national cooperative group trial, M-VAC was compared 
with single-agent cisplatin.15 Patients (269) were assigned 
to M-VAC or cisplatin, cycles repeated every 28 days until 
tumor progression or a maximum of six cycles. M-VAC 
regimen was associated with a greater toxicity, particularly 
leukopenia, mucositis, neutropenic fever, and drug-related 
mortality. Response rates were superior in the M-VAC 
arm compared with the single-agent cisplatin arm (39% vs 
12%) PFS (10.0 vs 4.3 months) and OS (12.5 vs 8.2 months) 
were significantly greater for the combined therapy arm. 
In another randomized trial with 110 patients,69 M-VAC 
was compared with a regimen consisting of cisplatin, 
cyclophosphamide, and doxorubin (CISCA); M-VAC arm 
showed significantly higher response rate (65% vs 46%) and 
median survival (48 vs 36 weeks) compared with CISCA. 
In attempts to translate response rates to improved survival 
rates, high-dose intensity M-VAC was evaluated in an 
EORTC Phase III clinical trial (protocol #30924)70 with a 
recent 7-year update of the results.71 Patients (263) were 
randomly assigned to high-dose M-VAC given at 2-week 
intervals with growth factor support or to standard M-VAC 
given every 4 weeks. ORR (63% vs 50%), CR (21% vs 9%), 
and PFS (9.1 vs 8.2 months) were improved but there was 
no difference in OS, which was the primary endpoint (15.5 
vs 14.1 months). In the subsequent update with more than 
7 years of follow-up, high dose M-VAC showed a border-
line statistically significant relative reduction in the risk 
of death at 5 years (21.8% vs 13.5%; hazard ratio = 0.76) 
compared with M-VAC. Toxicity is a major consideration 
with M-VAC particularly myelosupression, neutropenic 
fevers, sepsis, and mucositis, with significant toxicity-related 
deaths reported in most clinical trials evaluating M-VAC. 
High dose M-VAC is considered standard of care at some 
centers, but not all.
In Phase II clinical trials, gemcitabine in combination 
with cisplatin have shown response rates of about 50% with 
a median survival of around 14 months.72,73 Based on these 
results, this combination was evaluated in a randomized 
Phase III trial of 405 patients, comparing it with M-VAC.45 
Chemotherapy was administered every 4 weeks for a maxi-
mum of six cycles. More patients in the GC arm completed 
the planned six cycles of therapy with fewer dose adjustments 
and significantly fewer patients with neutropenia and related 
complications, and toxicity-related deaths. The ORR (49% 
vs 46%), TTP (7.4 vs 7.4 months), and median survival 
(13.8 vs 14.8 months) were similar in both groups. This 
study demonstrated that GC had a better safety profile and 
tolerability while providing similar survival benefit compared 
with M-VAC. An updated analysis showed similar 5-year 
survival rates between the two regimens.17 Based on its 
similar efficacy and lower toxicity, GC rather than M-VAC OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
105
Treatment of invasive and metastatic bladder cancer
is considered by many to be the standard first-line regimen 
for patients with advanced urothelial bladder cancer.
Addition of paclitaxel to GC was evaluated in a Phase III 
clinical trial by EORTC (protocol #30987),74 which enrolled 
627 chemotherapy-naïve patients with advanced urothelial 
carcinoma, 81% of whom had primary bladder tumors. 
  Chemotherapy was administered for a maximum of six 
cycles. Both regimens were well tolerated overall. Results 
showed that the triplet combination had a higher rate of ORR 
(57% vs 46%) and CR (15% vs 10%); though the survival 
was 3 months longer (15.7 vs 12.8 months) in the 3-drug 
arm, it was not statistically different from GC.
Combination of docetaxel and cisplatin (DC) has been 
compared with M-VAC in a multicenter Phase III clini-
cal trial by the Hellenic Co-operative Oncology group.75 
Patients (220) were randomly assigned to M-VAC every 4 
weeks vs docetaxel plus cisplatin every 3 weeks. Treatment 
with M-VAC resulted in significantly superior RR (54.2% 
vs 37.4%), median TTP (9.4 vs 6.1 months), and median 
survival (14.2 vs 9.3 months), suggesting that M-VAC was 
superior to DC. Toxicity of M-VAC was considerably lower 
than that previously reported for M-VAC administered 
without G-CSF.
A Phase II trial76 comparing gemcitabine plus   carboplatin 
with GC and an Eastern co-operative Oncology group 
(ECOG) Phase III trial77 comparing M-VAC with carboplatin 
plus paclitaxel have evaluated carboplatin-based regimens, 
but have not established the equivalence of carboplatin to 
cisplatin. A recent EORTC trial78 (protocol #30986) has 
compared gemcitabine plus carboplatin with methotrexate, 
carboplatin plus vinblastine (M-CAVI) in patients with 
advanced urothelial cancer who are ‘unfit’ to receive cisplatin 
due to renal dysfunction or other medical comorbidities. With 
178 patients enrolled, this study showed an ORR of 42% for 
gemcitabine plus carboplatin and 30% for that M-CAVI, 
suggesting that both these regimens are active in this group 
of cisplatin ‘unfit’ patients. Age alone is not a contraindica-
tion for cisplatin use.
Two Phase II studies have reported antitumor efficacy of 
the combination of gemcitabine with pemetrexed, a folate 
antimetabolite, in patients with untreated metastatic urothe-
lial cancer, demonstrating a moderate antitumor activity at 
the expense of significant myelosuppression. In the ECOG 
study (E4802),79 with a cohort of 46 patients treated for a 
maximum of six cycles, the ORR was 31.8%; median TTP 
was 5.8 months with a median OS of 13.4 months. The most 
common grade $3 toxicity was neutropenia (75%) with 11% 
febrile neutropenia. In an earlier study of 64 patients,80 the 
reported ORR was 20% in the intention-to-treat   population 
(28% among the 47 patients evaluable for response); median 
OS was 10.3 months. Significant grade $3 toxicity included 
neutropenia (38%) with febrile neutropenia (17%) and ane-
mia (19%).
Eribulin, currently approved by the US Food and Drug 
Administration (FDA) to treat patients with metastatic breast 
cancer based on the results of a Phase III EMBRACE trial,81 
is a synthetic analog of halichondrin B and a potent inhibitor 
of microtubule dynamics. Preliminary results from an ongo-
ing Phase II trial evaluating eribulin in patients with urothelial 
cancer with no prior cytotoxic therapy for advanced disease 
(neo/adjuvant therapy allowed) was recently reported.82 
Results of the 37 evaluable patients demonstrated an ORR 
of 38% and a RR of 34% in patients who had received prior 
neo/adjuvant therapy. At a median follow-up of 19.8 months, 
the PFS was 3.9 months and a median OS of 9.4 months, 
suggesting promising activity of eribulin in this group of 
patients. The most common grade $3 toxicity reported was 
neutropenia (54%). Its safety and efficacy in combination 
with GC is currently being evaluated in a Phase I/II study 
(Table 2).
With a better understanding of tumor biology including a 
few upregulated/dysregulated signaling pathways   (Figure 1) 
in urothelial cancer,83 several agents that act against spe-
cific targets among these signaling pathways, particularly 
vascular endothelial growth factor receptor (VEGFR) (eg, 
bevacizumab), epithelial growth factor receptor (EGFR) (eg, 
cetuximab), and mammalian target of rapamycin (mTOR) 
(eg, everolimus) are currently being tested in first-line therapy 
in combination with cytotoxic chemotherapy for patients 
with advanced bladder cancers, some of the agents showing 
promising results (Table 3; Figure 1).
Bevacizumab has been studied in combination with GC 
as first-line therapy for metastatic urothelial carcinoma in a 
Phase II trial by the Hoosier Oncology group84 (GU 04-75). 
In this single-arm study, 43 patients received GC along with 
bevacizumab 15 mg/kg every 3 weeks. Known antiangio-
genic treatment-related toxicities (bleeding, thromboembo-
lism) were common. The ORR was 72% with a CR of 21%, 
another 16% having stable disease. At a median follow-up of 
27.2 months, PFS was 8.2 months with an OS of 20.4 months, 
suggesting that the combination of GC and bevacizumab is 
an active first-line regimen in metastatic bladder cancer. This 
is now being tested in a large Phase III trial (Table 3).
Human epidermal growth factor receptor-2 (Her2/neu, 
c-erbB2) expression and efficacy of combining trastuzumab 
(a humanized monoclonal antibody that binds to Her2/neu) OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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with first-line therapy of recurrent and/or metastatic Her2/neu-
positive urothelial cancers was reported in a Phase II study.85 
Expression of Her2/neu in urothelial cancers can be vari-
able, ranging from 8.5% to 81%, and in this study 52.3% 
of the tumors were positive (57 of the 109 screened cases). 
Her-2/neu-positive patients had more metastatic sites and 
visceral metastasis than did Her-2/neu-negative patients. 
Forty-four of the 57 Her-2/neu-positive patients were treated 
with combination of transtuzumab, paclitaxel, carboplatin, 
and gemcitabine. The median number of chemotherapy 
Table 3 Select active clinical trials for first-line therapy in advanced and metastatic bladder cancer100
Study identifier Phase Study drug Start date Primary endpoint
NCT00461851 ii gemcitabine + carboplatin + sorafenib April 2007 TTP
NCT01126749 i/ii eribulin + gemcitabine + cisplatin May 2010 Safety
NCT00635726 ii methotrexate + vinblastine + doxorubicin + cisplatin followed  
by gemcitabine + cisplatin
March 2008 ORR
NCT00645593 ii gemcitabine + cisplatin ± cetuximab March 2008 ORR
NCT00995488 ii nab-paclitaxel + gemcitabine + carboplatin October 2009 Efficacy
NCT01118039 ii sunitinib (cisplatin ineligible patients) May 2010 TTP and safety
NCT01191892 ii gemcitabine + carboplatin ± vandetanib August 2009 PFS
NCT01089088 ii gemcitabine + cisplatin + sunitinib March 2010 PFS
NCT01090466 i/ii gemcitabine + cisplatin + temsirolimus March 2010 PFS and safety
NCT01215136 ii everolimus ± paclitaxel (cisplatin ineligible patients) October 2010 ORR
NCT00949455 ii/iii lapatinib maintenance in HeR-2+ bladder cancer after  
first-line chemotherapy
July 2009 PFS
NCT00625664 iii larotaxel + cisplatin vs gemcitabine + cisplatin (CiLAB) February 2008 OS
NCT00942331 iii gemcitabine + cisplatin ± bevacizumab July 2009 OS
NCT00022191 iii gemcitabine + cisplatin ± paclitaxel August 2001 OS
NCT00089128 ii gemcitabine + irinotecan August 2004 ORR
NCT00478361 ii gemcitabine + paclitaxel + doxorubicin with pegfligrastim May 2007 ORR, TTP, and survival
Abbreviations: TTP, time to progression; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
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Figure 1 Dysregulated signaling pathways and targeted therapy in bladder cancer.
Abbreviations: eGF, epithelial Growth Factor; VeGF, Vascular endothelial Growth Factor; iGF-1, insulin-like Growth Factor-1; RTK, Receptor Tyrosine Kinase; mTOR, 
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cycles administered was six. The ORR was an impressive 
70%; median TTP was 9.3 months and median OS was 
14.1 months. Most common grade 3–4 toxicities were myelo-
suppression and sensory neuropathy; grade 3 cardiac toxicity 
was reported in two patients (4.5%). Though the results are 
very promising, there appears no consensus on routinely 
screening for Her-2/neu expression on all bladder cancer 
specimens. Based on these results a prospective clinical Phase 
III study with paclitaxel, carboplatin, and gemcitabine, with 
or without trastuzumab, is clearly warranted.
Second-line therapy
An effective salvage therapy for relapsed urothelial cancer 
following first-line chemotherapy has remained an unmet 
need despite several research efforts. Frequently there 
is a significant deterioration in the overall clinical condition, 
often associated with renal impairment after progression 
following first-line therapy, which makes it difficult to 
enroll them in clinical trials, or even administer systemic 
chemotherapy off-study protocol. In several clinical tri-
als, the reported response rates with single agents such as 
paclitaxel,79 ifosphamide,86 docetaxel,65 and gemcitabine64 has 
been about 20% or less. Combinations such as paclitaxel with 
gemcitabine,70,87 oxaliplatin with 5-fluorouracil (FOLFOX),88 
or gemcitabine (GEM-OX)89 after failing M-VAC have dem-
onstrated response rates in the range of 20% to 27% but with 
significant toxicities such as neutropenia, thrombocytopenia, 
and peripheral neuropathy. Currently, there is no defined 
standard second-line therapy for metastatic bladder cancer. 
Some of the more recent trials with (promising) results will 
be reviewed in this section.
Vinflunine is a novel, biflourinated, third-generation, 
vinca alkaloid, antimitotic agent that has demonstrated 
superior antitumor activity to other agents in its class.90 The 
efficacy of vinflunine as a second-line therapy for patients 
with relapsed or refractory advanced urothelial cancer 
after first-line platinum-containing chemotherapy has been 
evaluated in 3 open-label, multicenter studies.91–93 In the two 
Phase II studies, vinflunine demonstrated moderate antitumor 
activity with a RR of 15%93 and 18%.92 The Phase III trial 
compared vinflunine plus best supportive care (BSC) with 
BSC alone. Patients (370) were randomly assigned in a 2:1 
ratio to receive vinflunine plus BSC (n = 253) or BSC alone 
(n = 117). Both arms were well balanced except there were 
more patients with performance status .1 (10% difference) 
in the BSC arm. Most common grade $3 toxicities for vinflu-
nine arm were neutropenia (50%), febrile neutropenia (6%), 
anemia (19%), fatigue (19%), and constipation (16%). In the 
intent-to-treat population, the objective of a median 2-month 
survival advantage (6.9 months for vinflunine plus BSC vs 
4.6 months for BSC) was achieved but was not statistically 
significant (P = 0.287). Multivariate Cox analysis adjust-
ing for prognostic factors showed a statistically significant 
effect of vinflunine on OS (P = 0.036), reducing the death 
risk by 23%. ORR (8.6% vs 0%), disease control (41.4% vs 
24.8%), and PFS (3.0 vs 1.5 months) were all statistically 
significant, favoring vinflunine. With an acceptable safety 
profile, vinflunine appears to be a reasonable second-line 
therapy option for patients with bladder cancer who have 
relapsed following cisplatin-based therapy.
In a recent randomized Phase III trial by German 
  Association of Urological Oncology (AB 20/99),94 short-
term (maximum of six cycles every 3 weeks) vs prolonged 
therapy (treatment continued until disease progression) with 
a combination of gemcitabine with paclitaxel was evaluated 
as second-line chemotherapeutic treatment for patients with 
metastatic urothelial cancer after failure of cisplatin-based 
first-line therapy. Of the 102 enrolled patients 96 were 
eligible for analysis. The results showed that there was no 
difference in OS (7.8 vs 8.0 months), PFS (4 vs 3.1 months), 
or ORR (37.5% vs 41.5%) between the short-term and pro-
longed therapy. More patients had severe anemia (26% vs 
6.7%) in the prolonged treatment arm. The high response 
rate (∼40%) suggests that the combination of gemcitabine 
and paclitaxel is a reasonable option as second-line therapy 
in this group of patients.
Activity of single-agent pemetrexed as a second-line 
therapy in patients with urothelial cancer was reported by the 
Hoosier Oncology Group.95 Forty-seven patients were enrolled 
and included in the intention-to-treat efficacy analysis. The 
ORR was 27.7%, median TTP was 2.9 months, median dura-
tion of response was 5 months, and median OS was 9.6 months, 
fatigue and myelosupression accounting for the most common 
grade 3–4 toxicity. This study supports pemetrexed as a reason-
able second-line therapy option in this patient population.
Results of a Phase II study evaluating single-agent 
  nab-paclitaxel, the albumin-bound nanoparticle formulation, 
in a cohort of 48 patients with urothelial cancer who had 
progressed or relapsed after cisplatin-based chemotherapy 
was recently presented. ORR in 47 evaluable patients was 
32%. With an additional 21% of patients having stable dis-
ease, the clinical benefit rate (CBR) was 53%, representing 
one of the highest reported RRs in the second-line therapy of 
urothelial cancer. Nab-paclitaxel was well tolerated and the 
most frequent grade $3 adverse events reported were pain 
(45%), hypertension (14%), and fatigue (8%).OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Ixabepilone, an epothilone B analog, which binds to 
β-tubulin and stabilizes microtubules, has shown promising 
activity in several solid tumors and is currently approved 
by FDA for treatment of metastatic breast cancer.96 Its 
efficacy in urothelial cancer was evaluated in a Phase II 
trial by ECOG (E3800).97 In this study of 45 patients, ORR 
was a dismal 11.9% with a median survival of 8 months. 
Toxicity was moderate, granulocytopenia, fatigue, and 
sensory neuropathy being the most common side-effects 
reported.
Signaling through VEGFR and EGFR pathways is 
thought to play a critical role in growth and progression 
of urothelial cancers.83 Several molecularly targeted 
approaches are currently under investigation as second-line 
therapies in recurrent/refractory bladder cancers (Table 4). 
A recent report of a multicenter, noncomparative random-
ized Phase II study98 of cetuximab with or without paclitaxel 
in patients with previously treated metastatic urothelial 
cancer suggests that EGFR inhibition with cetuximab 
enhances the antitumor activity of paclitaxel in this setting. 
Thirty-nine evaluable patients were enrolled. The cetuximab 
arm was closed after nine of the first eleven patients pro-
gressed by 8 weeks. ORR was 28.5%, and median PFS for 
cetuximab-paclitaxel arm was 3.8 months with a median 
OS of 9.5 months. Pazopanib, a second-generation multitar-
geted tyrosine kinase inhibitor (TKi) of VEGFR-1, 2, and 3, 
platelet-derived growth factor receptor, and c-kit, has shown 
promising results as a single agent in an ongoing Phase II 
trial in heavily pretreated patients with relapsed or refrac-
tory urothelial cancer.99 In total, 18 patients were enrolled 
until July 2010, 10 patients having primary bladder tumor; 
22% of patients had partial response and 61% had stable 
disease with a CBR of 83%. The drug was well tolerated 
overall, with grade $3 nausea or anorexia reported in two 
patients and hypertension in one patient. More patients need 
to be enrolled and longer follow-up is required. A Phase II 
study evaluating   single-agent aflibercept, a soluble recep-
tor for VEGF, also known as VEGF Trap, in urothelial 
cancer patients who have failed cisplatinum-based therapy 
has completed accrual but results are not yet reported.100 
Clinical trials with other targeted agents such as lapatinib 
(HER-2 and EGFR TKi), erlotinib (HER-1 and HER-2 
TKi), sunitinib (multiple receptor TKi), and everolimus 
(mTOR inhibitor) are ongoing (Table 4).
Management of variants and 
nonurothelial cell malignancies  
of the bladder
Primary nonurothelial bladder malignancies are rare, rep-
resenting less than 10% of all bladder cancers. The recent 
World Health Organization classification of urothelial 
cancers lists 13 different histologic variants of urothelial 
cancer101 (Table 5). The divergent differentiation patterns 
such as squamous, glandular (adenocarcinoma), micropapil-
lary, nested, plasmacytoid, and carcinosarcoma/sarcomatoid 
variants should be identified because of the potential for 
having an unfavorable prognosis despite aggressive surgical 
management that relates both to an aggressive biological 
behavior and also often due to an advanced stage at the time 
of diagnosis.
Squamous cell carcinoma (SCC) is the second most 
prevalent epithelial neoplasm of the bladder, accounting 
for approximately 3% to 5% of bladder tumors in Western 
countries.102 While the pathogenesis of SCC of the bladder 
is only been partly understood, it is thought to involve fac-
tors that result in chronic bladder infection and irritation. 
SCC of the bladder in countries of the Middle East and 
Egypt has a distinct pathogenesis that is linked to chronic 
Table 4 Select active clinical trials in second-line therapy for advanced and metastatic bladder cancer100
Study identifier Phase Study drug Start date Primary endpoint
NCT01265940 i/ii pazopanib + vinflunine Dec 2010 PFS
NCT00365157 i/ii e7389 (halichondrin B analog) October 2010 Response rate and safety
NCT00683059 ii nab-paclitaxel May 2008 Response rate
NCT00578526 ii sunitinib (SPRUCe) December 2007 PFS
NCT01282463 ii Docetaxel ± ramucirumab or iMC-18F1 January 2011 PFS
NCT01234519 i/ii AeZS-108 in LHRH + urothelial cancers November 2010 MTD
NCT00722553 ii pralatrexate July 2008 ORR
NCT01031875 ii pazopanib December 2009 ORR
NCT01108055 ii pazopanib + paclitaxel April 2010 ORR
NCT00933374 ii everolimus + paclitaxel July 2009 ORR
Abbreviations: PFS, progression-free survival; MTD, maximum tolerated dose; ORR, objective response rate; AeZS-108, luteinizing-hormone-releasing hormone linked 
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  infections with Schistosoma haematobium. In regions 
where this water-borne parasitic pathogen is endemic, SCC 
not only represents the most common histological type of 
bladder tumor, but also the most prevalent form of cancer 
in men overall, accounting for 30% of cancers.   Preoperative 
radiation has been shown to decrease pelvic recurrence in 
a single-institution study, but this remains of uncertain 
benefit.103 Standard chemotherapy regimens appear to have 
limited impact on the disease due to the relative chemoresis-
tance of SCC. The use of chemotherapy regimens, such as 
the combination of paclitaxel, carboplatin, and gemcitabine, 
which have demonstrated efficacy in patients with SCC of 
other locations such as lung, head, and neck, may offer better 
outcomes.85 Standard treatment of Schistosoma-associated 
SCC is radical cystectomy and urinary diversion. A potential 
role for neoadjuvant or adjuvant radiation and chemotherapy 
remains poorly defined.
Pure adenocarcinoma of the bladder represents the third 
most common type of epithelial tumor comprising 0.5% to 
2.0% of all bladder tumors.102 In advanced cases of adeno-
carcinoma of the bladder, conventional chemotherapy (eg, 
M-VAC) is not effective, and hence the use of chemother-
apy or radiotherapy should be individualized and may be 
of potential benefit in select patients. A recent SEER-based 
analysis showed that while patients with adenocarcinoma of 
the bladder undergo radical cystectomy at more advanced 
disease stage, the stage- and grade-adjusted cancer-specific 
mortality is the same among patients with adenocarcinoma 
and urothelial carcinoma of the bladder.104 Primary small 
cell or neuroendocrine carcinoma of the bladder is an 
extremely uncommon, aggressive, poorly differentiated 
neoplasm that is similar to small cell carcinoma of the 
lung in clinical behavior and accounts for less than 0.7% 
of all bladder tumors. A report from Mayo Clinic suggest 
that more than half the patients had metastatic spread to 
the loco-regional lymph nodes, liver, or bone at the time 
of presentation.105 Chemotherapy regimens similar to 
those used in small cell lung cancer of the lung have been 
employed and shown to be of benefit in several retrospec-
tive studies.105,106
Sarcoma, a malignant mesenchymal tumor, and carci-
nosarcoma, a biphasic mixture of carcinoma and sarcoma, 
have very rare occurrence in the bladder with only a few 
case series reported to date.107–109 Metastatic sarcomas 
and carcinosarcomas are frequently treated by employing 
multimodality protocols including resection, radiation, and 
chemotherapy. Doxorubicin and ifosfamide appear to be the 
most active single agents.108 A case report suggested benefit 
using gemcitabine with cisplatin in a patient with metastatic 
sarcomatoid carcinoma.110
Overall, for patients with metastatic nonurothelial blad-
der cancers, patient management should be based upon the 
histology of the primary tumor. Given the absence of data 
showing a survival or quality-of-life benefit from chemo-
therapy for these diseases, palliative care as an alternative to 
chemotherapy should be offered. Those electing to receive 
chemotherapy should be encouraged to consider enrolling in 
a clinical trial if an appropriate trial is available.
Concluding remarks
Bladder cancer comprises a variety of diseases. While most 
patients with superficial cancers do not encounter a life-
threatening condition, several patients with invasive disease 
do. In this group of patients, choosing the appropriate 
systemic regimen and timing of institution of such therapy 
is crucial. Based on the review of the multiple randomized 
clinical trials and meta-analysis, the treatment paradigm 
for muscle-invasive bladder cancer has shifted from cystec-
tomy alone towards the use of cisplatin-based neoadjuvant 
chemotherapy. Further, development of gene expression 
models (eg, 20-gene GEM) will allow patients who would 
benefit from such therapy to be identified more accurately. 
Understanding the biology and various pathways involved in 
development of invasive bladder cancer has led to evaluation 
of targeted therapy (eg, VEGFR and EGFR pathways and 
use of multityrosine TKi) in combination with conventional 
cytotoxic chemotherapy, and the results from such clinical tri-
als are promising. Though the progress in the field of bladder 
cancer has been slow, the future looks bright. In view of the 
multitude of questions still unanswered, every patient with 
Table 5 Variants of invasive urothelial carcinoma
  1. Squamous cell carcinoma
  2. Adenocarcinoma
  3. Nested pattern
  4. Microcystic
  5. Micropapillary
  6. Lympho-epithelioma-like
  7. Plasmacytoid and lymphoma-like
  8. Sarcomatoid/carcinosarcoma
  9. Giant cell
10. Trophoblastic differentiation
11. Clear cell
12. Lipid cell
13. Undifferentiated
Note: Adapted from World Health Organization Classification of Tumours. IARC 
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advanced bladder cancer should be encouraged to participate   
in clinical trials. Patients, physicians, and families should 
support each other in the quest to cure more patients and 
minimize mortality of bladder cancer.
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